病情控制良好的RA和JIA孕妇孕20周前停用TNF抑制剂与孕晚期病情恶化无关
该前瞻性队列研究纳入490例RA和JIA孕妇,评估孕20周前停用TNF抑制剂是否与病程变化相关。结果显示,在入组时病情低至轻微活动的孕妇中,停用TNF抑制剂与孕晚期患者报告结局的临床重要恶化无关。
要点
- 病情控制良好的RA和JIA孕妇在孕20周前停用TNF抑制剂似乎是可行的。
- 停用TNF抑制剂未导致孕晚期患者报告结局出现临床重要恶化。
- 多因素分析未显示孕20周后继续使用TNF抑制剂与疾病活动度改善独立相关。
核心结论
- 在入组时病情控制良好的RA和JIA孕妇中,孕20周前停用TNF抑制剂与孕晚期患者报告结局的临床重要恶化无关。
研究设计与样本
- 前瞻性队列研究,纳入2005至2017年间来自美国和加拿大的490例RA和JIA孕妇(RA 397例,JIA 93例)。
主要发现
- 122例(24.9%)在孕20周前停用TNF抑制剂,201例(41.0%)在孕20周后继续使用,167例(34.1%)孕期未使用TNF抑制剂。
- 入组时72.9%的孕妇疾病活动度为低至轻微。
- 停用TNF抑制剂与孕晚期患者报告结局的临床重要恶化无关。
- 单因素分析显示孕20周后继续使用TNF抑制剂者孕晚期疾病活动度评分改善更可能,但多因素分析无此关联。
临床怎么用
- 对于进入孕期时病情控制良好的RA和JIA孕妇,可考虑在孕20周前停用TNF抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether the discontinuation of tumor necrosis factor inhibitors (TNFi) during pregnancy is associated with any changes of the disease course in women with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). METHODS: Pregnant women with RA and JIA from the US and Canada were enrolled in the Organization of Teratology Information Specialists (OTIS) Autoimmune Diseases in Pregnancy Project, a prospective cohort study. Information about medication and disease activity (patient-reported outcome measures) was collected prior to gestational week 20 and at gestational week 32. Associations between patterns of TNFi continuation or discontinuation and disease activity changes were tested in unadjusted and multivariate analyses. RESULTS: Among 490 women (397 with RA, 93 with JIA) enrolled between 2005 and 2017, 122 (24.9%) discontinued a TNFi before gestational week 20, 201 (41.0%) received a TNFi beyond week 20, and 167 (34.1%) did not receive a TNFi during pregnancy. At the time of enrollment, disease activity was low to minimal in 72.9% of women. TNFi discontinuation was not associated with a clinically important worsening of patient reported outcome measures at the third trimester. Univariate but not multivariate analysis showed that women receiving TNFi beyond week 20 were more likely to experience improved disease activity scores at the third trimester. CONCLUSION: Discontinuing TNFi before gestational week 20 seems feasible in women with RA and JIA who enter pregnancy with well-controlled disease.
引用
- Förger F, Bandoli G, Luo Y, et al. No Association of Discontinuing Tumor Necrosis Factor Inhibitors Before Gestational Week Twenty in Well-Controlled Rheumatoid Arthritis and Juvenile Idiopathic Arthritis With a Disease Worsening in Late Pregnancy. Arthritis Rheumatol. 2019. PMID: 30663847. doi:10.1002/art.40821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。